[1] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492
|
[2] |
HU JH, YUAN PZ, LI Y. The value of serum glutamate dehydrogenase and cholinesterase in the diagnosis of liver diseases[J]. Prac J Clin Med, 2019, 16(3): 115-117. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YYLC201903036.htm
胡江红, 袁平宗, 李勇. 血清谷氨酸脱氢酶与胆碱酯酶诊断肝脏疾病价值分析[J]. 实用医院临床杂志, 2019, 16(3): 115-117. https://www.cnki.com.cn/Article/CJFDTOTAL-YYLC201903036.htm
|
[3] |
KITAHARA CM, BERRINGTON de GONZÁLEZ A, FREEDMAN ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea[J]. J Clin Oncol, 2011, 29(12): 1592-1598. DOI: 10.1200/JCO.2010.31.5200
|
[4] |
GAO XH, ZHANG SS, CHEN H, et al. Systemic hepatic-damage index for predicting the prognosis of hepatocellular carcinoma after curative resection[J]. Front Physiol, 2017, 8: 480. DOI: 10.3389/fphys.2017.00480
|
[5] |
National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic criteria of alcoholic fatty liver disease[J]. World J Infect, 2001, 1(5): 482. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZHGZ200302003.htm
中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 酒精性肝病诊断标准[J]. 世界感染杂志, 2001, 1(5): 482. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHGZ200302003.htm
|
[6] |
Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.007
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007
|
[7] |
LI D, ZHAO H, ZHOU H, et al. The clinical characteristics and the image presentation of CT and MRI of hepatocellular carcinoma based on alcoholic liver cirrhosis[J]. J Med Sci Cent South China, 2015, 43(6): 632-636. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-HYYY201506009.htm
李丹, 赵衡, 周宏, 等. 酒精相关性肝细胞癌的临床特点和CT、MRI影像表现[J]. 中南医学科学杂志, 2015, 43(6): 632-636. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYY201506009.htm
|
[8] |
COSTENTIN CE, MOURAD A, LAHMEK P, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study[J]. Cancer, 2018, 124(9): 1964-1972. DOI: 10.1002/cncr.31215
|
[9] |
GEORGILA K, VYRLA D, DRAKOS E. Apolipoprotein A-Ⅰ (ApoA-Ⅰ), immunity, inflammation and cancer[J]. Cancers (Basel), 2019, 11(8): 1097. DOI: 10.3390/cancers11081097
|
[10] |
YE J, LUO Q Y, WANG X P, et al. Serum apolipoprotein A-Ⅰ combined with C-reactive protein serves as a novel prognostic stratification system for colorectal cancer[J]. Cancer Manag Res, 2019, 11: 9265-9276. DOI: 10.2147/CMAR.S215599
|
[11] |
TATEMATSU S, FRANCIS SA, NATARAJAN P, et al. Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium[J]. Arterioscler Thromb Vasc Biol, 2013, 33(8): 1788-1794. DOI: 10.1161/ATVBAHA.113.301300
|
[12] |
QIAO XW. Detection and analysis of blood lipid level in patients with liver cancer[J]. Chron Pathematol J, 2010, 12(10): 1242, 1244. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YYSO201010053.htm
乔献伟. 肝癌患者血脂水平检测分析[J]. 慢性病学杂志, 2010, 12(10): 1242, 1244. https://www.cnki.com.cn/Article/CJFDTOTAL-YYSO201010053.htm
|
[13] |
TRIEB M, RAINER F, STADLBAUER V, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure[J]. J Hepatol, 2020, 73(1): 113-120. DOI: 10.1016/j.jhep.2020.01.026
|
[14] |
OOI K, SHIRAKI K, SAKURAI Y, et al. Clinical significance of abnormal lipoprotein patterns in liver diseases[J]. Int J Mol Med, 2005, 15(4): 655-660. http://europepmc.org/abstract/MED/15754028
|
[15] |
MOTTA M, GIUGNO I, RUELLO P, et al. Lipoprotein (a) behaviour in patients with hepatocellular carcinoma[J]. Minerva Med, 2001, 92(5): 301-305. http://www.ncbi.nlm.nih.gov/pubmed/11675573
|
[16] |
FUJII S, KOGA S, SHONO T, et al. Serum apoprotein A-Ⅰ and A-Ⅱ levels in liver diseases and cholestasis[J]. Clin Chim Acta, 1981, 115(3): 321-331. DOI: 10.1016/0009-8981(81)90245-X
|
[17] |
HUANG WC, CHEN X, YU JL, et al. Value of serum high-density lipoprotein cholesterol levels in evaluating liver function[J]. China Med Pharm, 2014, 4(13): 118-119, 142. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-GYKX201413044.htm
黄文彩, 陈璇, 余洁玲, 等. 血清高密度脂蛋白胆固醇水平用于评价肝脏合成功能的价值[J]. 中国医药科学, 2014, 4(13): 118-119, 142. https://www.cnki.com.cn/Article/CJFDTOTAL-GYKX201413044.htm
|
[18] |
BEEGHLY-FADIEL A, KHANKARI NK, DELAHANTY RJ, et al. A Mendelian randomization analysis of circulating lipid traits and breast cancer risk[J]. Int J Epidemiol, 2020, 49(4): 1117-1131. DOI: 10.1093/ije/dyz242
|
[19] |
ZHANG D, XI Y, FENG Y. Ovarian cancer risk in relation to blood lipid levels and hyperlipidemia: A systematic review and meta-analysis of observational epidemiologic studies[J]. Eur J Cancer Prev, 2020. [Online ahead of print] http://journals.lww.com/eurjcancerprev/Fulltext/9000/Ovarian_cancer_risk_in_relation_to_blood_lipid.99122.aspx
|
[20] |
SCHAIRER C, LAURENT CA, MOY LM, et al. Obesity and related conditions and risk of inflammatory breast cancer: A nested case-control study[J]. Breast Cancer Res Treat, 2020, 183(2): 467-478. DOI: 10.1007/s10549-020-05785-1
|
[21] |
QU F, CHEN R, PENG Y, et al. Assessment of the predictive role of serum lipid profiles in breast cancer patients receiving neoadjuvant chemotherapy[J]. J Breast Cancer, 2020, 23(3): 246-258. DOI: 10.4048/jbc.2020.23.e32
|
[22] |
GANJALI S, BANACH M, PIRRO M, et al. HDL and cancer-causality still needs to be confirmed? Update 2020[J]. Semin Cancer Biol, 2020. [Online ahead of print] http://www.sciencedirect.com/science/article/pii/S1044579X20302121
|
[23] |
YU JF. Analysis of abnormal levels of blood lipid and homocysteine in patients with different types of malignant tumors[D]. Nanning: Guangxi Medical University), 2017. (in Chinese)
余敬福. 不同类型恶性肿瘤患者血脂、同型半胱氨酸水平异常分析[D]. 南宁: 广西医科大学, 2017.
|
[24] |
ZOU Y, WU L, YANG Y, et al. Serum lipid levels correlate to the progression of gastric cancer with neuroendocrine immunophenotypes: A multicenter retrospective study[J]. Transl Oncol, 2021, 14(1): 100925. DOI: 10.1016/j.tranon.2020.100925
|
[25] |
BRANTLEY KD, RIIS AH, ERICHSEN R, et al. The association of serum lipid levels with colorectal cancer recurrence[J]. Cancer Epidemiol, 2020, 66: 101725. DOI: 10.1016/j.canep.2020.101725
|
[26] |
YUAN B, FU J, YU WL, et al. Prognostic value of serum high-density lipoprotein cholesterol in patients with gallbladder cancer[J]. Rev Esp Enferm Dig, 2019, 111(11): 839-845. http://www.ncbi.nlm.nih.gov/pubmed/31595756
|
[27] |
SAITO N, SAIRENCHI T, IRIE F, et al. Low serum LDL cholesterol levels are associated with elevated mortality from liver cancer in Japan: The Ibaraki Prefectural health study[J]. Tohoku J Exp Med, 2013, 229(3): 203-211. DOI: 10.1620/tjem.229.203
|
[28] |
ZHAN CL. Serum makers of lipid metabolism as a new prognostic factor in cancer: A meta-analysis[D]. Suzhou: Soochow University, 2019. (in Chinese)
湛长丽. 血清脂代谢标志物作为恶性肿瘤预后预测因子的Meta分析[D]. 苏州: 苏州大学, 2019.
|
[29] |
JIANG SS, WENG DS, JIANG L, et al. The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma[J]. J Cancer, 2016, 7(6): 626-632. DOI: 10.7150/jca.13837
|
[30] |
CARR BI, GIANNELLI G, GUERRA V, et al. Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients[J]. Int J Biol Markers, 2018, 33(4): 423-431. DOI: 10.1177/1724600818776838
|
[31] |
ZHONG GC, HUANG SQ, PENG Y, et al. HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: A pooled analysis of 37 prospective cohort studies[J]. Eur J Prev Cardiol, 2020, 27(11): 1187-1203. DOI: 10.1177/2047487320914756
|